Insulet (PODD) Total Debt Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.34% |
| Dec 31, 2025 | -2.17% |
| Sep 30, 2025 | 1.95% |
| Jun 30, 2025 | 8.99% |
| Mar 31, 2025 | 13.53% |
| Dec 31, 2024 | 9.22% |
| Sep 30, 2024 | 7.24% |
| Jun 30, 2024 | 18.14% |
| Mar 31, 2024 | 18.51% |
| Dec 31, 2023 | 19.05% |
| Sep 30, 2023 | 19.43% |
| Jun 30, 2023 | 19.35% |
| Mar 31, 2023 | 19.63% |
| Dec 31, 2022 | 19.88% |
| Sep 30, 2022 | 32.46% |
| Jun 30, 2022 | 32.87% |
| Mar 31, 2022 | 33.28% |
| Dec 31, 2021 | 30.80% |
| Sep 30, 2021 | 31.34% |
| Jun 30, 2021 | 48.20% |
| Mar 31, 2021 | 43.78% |
| Dec 31, 2020 | 43.90% |
| Sep 30, 2020 | 39.59% |
| Jun 30, 2020 | 39.51% |
| Mar 31, 2020 | 39.43% |
| Dec 31, 2019 | 40.18% |
| Sep 30, 2019 | 42.56% |
| Jun 30, 2019 | 26.20% |
| Mar 31, 2019 | 38.83% |
| Dec 31, 2018 | 39.11% |
| Sep 30, 2018 | 39.38% |
| Jun 30, 2018 | 39.65% |
| Mar 31, 2018 | 36.35% |
| Dec 31, 2017 | 36.80% |
| Sep 30, 2017 | 24.43% |
| Jun 30, 2017 | 24.66% |
| Mar 31, 2017 | 24.89% |
| Dec 31, 2016 | 25.12% |
| Dec 31, 2015 | 19.85% |